Author

Ian C. Miller

Intellia Therapeutics (United States)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Synthetic Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:CRISPR screen· 1 Approach:deep learning· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Aaron ProdeusiD· 2 shared Allie Luther· 2 shared Birgit C. SchultesiD· 2 shared Dai LiuiD· 2 shared Ishina BalwaniiD· 2 shared Ivy Dutta· 2 shared Palak SharmaiD· 2 shared Qingzhan Zhang· 2 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersSynthetic Biology

Aaron ProdeusORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Engineering antigen-driven co-stimulation and T helper cell activity into TCR-T cells with CD8-41BB fusion receptors enhances anti-tumor activity

Ivy Dutta, Justin Oh, Liz Cam, Allie Luther, Palak Sharma, Ishina Balwani, James Peter, Dai Liu, Ian C. Miller, James R. Bowen, Lekshmi Maya, Jingyu Peng, Eleni Stampouloglou, Qingzhan Zhang, Yoko Kosaka, , Aaron Prodeus

This paper enhances TCR-T cell anti-tumor activity by engineering CD8-41BB fusion receptors, improving CD4+ and CD8+ T cell functions and tumor regression in mouse models.

bioRxiv · Jul 28, 2026 · PreprintSynthetic Biology

A differentiated and durable allogeneic strategy applicable to cell therapies

Utsav Jetley, Ishina Balwani, Palak Sharma, Ian C. Miller, Allie Luther, Ivy Dutta, Nithila Saravanan, Surbhi Goel, Qingzhan Zhang, Boning Zhang, Ozgun Kilic, Biao Liu, Bo Han, Dai Liu, Birgit C. Schultes, , Yong Zhang

This paper develops an allogeneic T cell therapy strategy using gene editing to reduce immune rejection and enable off-the-shelf use, showing comparable function to autologous cells.

Cytotherapy · Oct 11, 2025Peer-reviewedBioengineering